On Friday, CBRE Group Inc (NYSE:CBG)’s shares declined -2.24% to $37.69.
CBRE Group, Inc. (CBG) will release its second quarter 2015 financial results at about 6:30 a.m. Eastern time on Wednesday, July 29, 2015. Administration will hold a conference call to talk about these results at 8 a.m. Eastern time on that same day (Wednesday, July 29, 2015).
CBRE Group, Inc. operates as a commercial real estate services and investment company worldwide. The company operates through Americas; Europe, Middle East and Africa; Asia Pacific; Global Investment Administration; and Development Services segments. It provides advisory services, such as planned advice and execution to owners, investors, and occupiers of real estate in connection with leasing, disposition, and acquisition of property; integrated investment sales and debt/structured financing services under the CBRE Capital Markets brand; and valuation services, counting market value appraisals, litigation support, discounted cash flow analyses, feasibility and fairness opinions, and property condition and environmental consulting, in addition to originates and services commercial mortgage loans.
ASML Holding NV (ADR) (NASDAQ:ASML)’s shares dropped -3.34% to $98.53.
ASML Holding NV (ASML) an industry leader in developing lithography light sources used by chipmakers to pattern advanced semiconductor chips, recently declared a neon gas reduction program for the installed base of argon fluoride (ArF) and krypton fluoride (KrF) light sources. The program comprises new light source software to reduce neon consumption across the installed base of light sources, rapid qualification of new gas suppliers, and a light source upgrade to enable reclaim of used neon, allowing gas suppliers to reuse existing neon and further reduce the need for additional supplies. The neon gas reduction program has been put in place by Cymer to reduce dependence on neon, a key gas for operation of the light source, and to insulate our customers from fluctuations of neon supply.
ASML Holding N.V. engages in the development, production, marketing, sale, and servicing of advanced semiconductor equipment systems with a focus on lithography related systems worldwide. It provides PAS 5500 family products, which comprise wafer steppers, and step and scan systems with i-line, krypton fluoride, and argon fluoride light sources for processing wafers.
At the end of Friday’s trade, Textron Inc. (NYSE:TXT)‘s shares dipped -1.39% to $41.11.
Bell Boeing, a planned alliance between Bell Helicopter, a Textron [NYSE: TXT] company, and Boeing [NYSE: BA], was awarded a U.S. Navy contract recently for five Bell Boeing V-22 Osprey tiltrotor aircraft to be delivered to Japan, marking the first sale of the aircraft through the U.S. government’s foreign military sales program.
The contract for the Block C aircraft comprises support, training, and equipment. The versatile V-22 tiltrotor will allow Japan’s Ground Self-Defense Force greatly improved capabilities, while providing an ideal platform for relief efforts in response to natural disasters.
Textron Inc. operates in the aircraft, defense, industrial, and finance businesses worldwide. It operates through five segments: Textron Aviation, Bell, Textron Systems, Industrial, and Finance. The Textron Aviation segment manufactures business jets, turboprop aircraft, piston aircraft, military trainer and defense aircraft, and parts, in addition to provides maintenance, inspection, and repair services.
AstraZeneca plc (ADR) (NYSE:AZN), ended its Friday’s trading session with -50.58% loss, and closed at $32.89.
AstraZeneca plc (ADR) (AZN) declared that the U.S. Food and Drug Administration (FDA) has approved IRESSA® (gefitinib) as a first-line treatment in patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
IRESSA is a once daily oral EGFR-tyrosine kinase inhibitor (TKI), which inhibits the activity that contributes to intracellular signaling pathways implicated in the growth and survival of cancer cells. IRESSA was granted Orphan Drug Designation by the FDA in August 2014 for the treatment of EGFR mutation-positive advanced NSCLC.
AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. Its principal products comprise Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL to control hypertension, and heart failure and angina; Onglyza for diabetes mellitus; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
